- Home
- About Us
- Our Products
- Investors
- News
- New Product Pipeline
- Contact Us
Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.
Founded on an Australian discovery, Pharmaxis' products are now available worldwide. 

Pharmaxis has concluded a productive end to the review meeting with the United States FDA.

Pharmaxis has announced a revised business plan that delivers significant reductions in expenses and increases the focus on partnering strategies. 

Pharmaxis is pleased to announce the signing of a Financing Agreement with NovaQuest under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for CF in the EU and US.